Add BrightSurf on Google Email

University of Colorado Anschutz Medical Campus


Retinoic acid may improve immune response against melanoma

Researchers found that adding retinoic acid to standard-of-care treatment for melanoma can turn off myeloid-derived suppressor cells (MDSCs) that resist immune treatments, leading to increased immune system activity. The study showed a safe and promising strategy to target MDSCs, which could be a useful addition to immunotherapies for ...

SourceUniversity of Colorado Anschutz Medical Campus·JournalInternational Immunopharmacology·DateAug 16, 2018

Brain metastases common and difficult to treat in ROS1 lung cancer

A University of Colorado Cancer Center study found that brain metastases are a common occurrence in stage IV ROS1-positive non-small cell lung cancer. The study also showed that patients with ROS1 mutations had similar progression-free survival rates as ALK patients when treated with crizotinib, but with a higher risk of brain metastas...

SourceUniversity of Colorado Anschutz Medical Campus·JournalJournal of Thoracic Oncology·DateJul 10, 2018

In melanoma, radiosurgery may combine well with immunotherapy, especially PD-1 inhibitors

A University of Colorado Cancer Center study shows that combining radiosurgery with immunotherapy, especially PD-1 inhibitors, can significantly improve cancer control and overall survival in melanoma patients. The study found that patients treated with anti-PD-1 therapies had a median brain metastasis-free survival of not reached, whe...

SourceUniversity of Colorado Anschutz Medical Campus·JournalJournal of Neuro-Oncology·DateJun 25, 2018

Largest-ever study of thyroid cancer genetics finds new mutations, suggests immunotherapy

A large-scale study of thyroid cancer genetics has identified specific genes driving the disease and found that certain cancers can benefit from immunotherapy. The research also found amplifications of key receptor tyrosine kinases in anaplastic thyroid cancers, suggesting a potential target for treatment with lenvatinib.

SourceUniversity of Colorado Anschutz Medical Campus·JournalClinical Cancer Research·DateApr 26, 2018

CU Anschutz Medical Campus wins $46.5 million NIH grant to accelerate research discoveries

The University of Colorado Anschutz Medical Campus has received a $46.5 million NIH grant to enhance its translational science workforce and research environment. The grant will support the development of novel methodologies and resources to tackle rare diseases, improve health screenings in underserved communities, and reduce mortalit...

Opioid prescribing at veterans hospitals varies widely in treating chronic pain

A recent study found that Veterans Health Administration (VHA) facilities have varying care practices for military veterans with chronic pain, leading to inconsistent rates of long-term opioid therapy. Facilities with a wider range of non-opioid treatment options had lower rates of opioid use among veterans.

SourceUniversity of Colorado Anschutz Medical Campus·JournalJournal of General Internal Medicine·DateApr 24, 2018

Is whole-brain radiation still best for brain metastases from small-cell lung cancer?

A recent study found that stereotactic radiosurgery (SRS) can improve overall survival and reduce cognitive side-effects in patients with brain metastases from small-cell lung cancer. The study compared outcomes of 5,752 patients who received whole-brain radiation therapy (WBRT) to those of 200 patients who received SRS.

Researchers use health data to predict who will use opioids after hospitalization

Researchers developed a statistical model to predict hospitalized patients at risk of progressing to chronic opioid therapy. The model correctly identified high-risk patients in 79% of cases and was found to be highly associated with variables such as substance use disorder, benzodiazepine receipt, and surgical procedures during hospit...

SourceUniversity of Colorado Anschutz Medical Campus·JournalJournal of General Internal Medicine·DateMar 5, 2018